menu search

CVRX / CVRx: The Path To 7x Investment Returns

BaroStim Neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market, making it easier and faster to capture market share. The product has a clear path to scale through educating the workplace/increasing implantation centres across the U.S. and Europe. Read More
Posted: Jan 7 2022, 13:18
Author Name: Seeking Alpha
Views: 111775

CVRX News  

What Makes CVRx (CVRX) a New Strong Buy Stock

By Zacks Investment Research
October 31, 2023

What Makes CVRx (CVRX) a New Strong Buy Stock

CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive th more_horizontal

CVRx, Inc. (CVRX) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 26, 2023

CVRx, Inc. (CVRX) Q3 2023 Earnings Call Transcript

CVRx, Inc. (NASDAQ:CVRX ) Q3 2023 Earnings Conference Call October 26, 2023 5:30 PM ET Company Participants Mike Vallie - SVP-ICR Westwicke Nadim Yare more_horizontal

CVRX: BeAT-HF Overhang Now Fully Dealt With, Upsides Now In Motion, Reiterate Buy

By Seeking Alpha
September 3, 2023

CVRX: BeAT-HF Overhang Now Fully Dealt With, Upsides Now In Motion, Reiterate Buy

CVRx Inc's has recovered towards previous highs following the fallout of its BeAT-HF trial results in February 2023. Adoption and utilization of its B more_horizontal

CVRx, Inc. (CVRX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
July 25, 2023

CVRx, Inc. (CVRX) Q2 2023 Earnings Call Transcript

CVRx, Inc. (NASDAQ:CVRX ) Q2 2023 Earnings Conference Call July 25, 2023 5:30 PM ET Company Participants Mike Vallie – Senior Vice President-ICR Wes more_horizontal

CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
July 25, 2023

CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates

CVRx (CVRX) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.54 p more_horizontal

CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023

By GlobeNewsWire
July 11, 2023

CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023

MINNEAPOLIS, July 11, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing more_horizontal

CVRx (CVRX) Surges 7.2%: Is This an Indication of Further Gains?

By Zacks Investment Research
July 3, 2023

CVRx (CVRX) Surges 7.2%: Is This an Indication of Further Gains?

CVRx (CVRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions co more_horizontal

CVRx: Missing A Heartbeat

By Seeking Alpha
June 16, 2023

CVRx: Missing A Heartbeat

I called CVRx a highly risky but potentially lucrative investment at the time of the IPO in the summer of 2021. The company has seen solid revenue gro more_horizontal


Search within

Pages Search Results: